🇺🇸

US SEC Filing Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — March 26, 2026

Across 24 NASDAQ-100 related SEC filings from March 26, 2026, overarching themes include cost discipline driving narrower losses in biotech/agrotech (Arcadia Biosciences FY loss improved 31% YoY to $2.3M, MetaVia net loss down 53% to $13M), robust industrial performance (CMC Q2 FY26 EBITDA +114% YoY to $297.5M, Mueller 2025 net income +26.5% YoY to $765M), and financing for growth (Keurig $5.55B notes for JDE Peet’s acquisition, Arcadia $2.1M proceeds). Period-over-period trends show mixed revenues (4/10 with declines avg -15% YoY, e.g., Arcadia -4% FY), but operating expenses down avg 25% YoY across reporting firms, boosting margins in winners like CMC (+610 bps to 14%). Resource firms added reserves (Canadian Natural +4.5% to 15,910 MMBOE via acquisitions), while proxies signal governance evolution (Murphy USA declassification). Neutral 13G amendments from Vanguard indicate passive shifts without ownership changes. Critical implications: Industrials offer strength amid sector rotation, biotechs present turnaround plays with cash runways into late 2026, but leverage risks loom in deals like Keurig's.

11 high priority 13 medium 24 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (primarily banks, insurers, REITs, asset managers amid broader microcap/SPAC noise), sentiment skews mixed/neutral (32/50 filings), with 12 companies reporting YoY revenue growth averaging +13% (e.g., Lumexa +7.8%, Leef Brands +22.1%) offset by 11 declines averaging -28% (e.g., CaliberCos -60.7%, STRATA -9%). Net losses narrowed in 9 firms (avg improvement 35%) but widened in 8 (avg +18%), highlighting persistent profitability challenges despite asset growth in credit investors (MSD +40.7%, AB Private +16.9%). SPAC/de-SPAC and M&A activity dominates (18 filings), signaling Q2 2026 catalysts with $500M+ proceeds (e.g., Xanadu, Suncrete). Capital allocation leans conservative: dividends in REITs (BlackRock $0.96/share), buybacks/dividends in retail proxies (Williams Sonoma $862M buybacks + $327M divs), no major cuts. Forward-looking guidance stable (Lumexa reiterates 2026 rev $1.045-1.097B), but risks from delistings (FiscalNote), going concerns (Indigo SPAC), and leverage rises. Portfolio implications: Bullish on SPAC mergers and credit growth; bearish on revenue-dependent microcaps; watch NIM/ROE trends in banks/insurers for rate sensitivity.

37 high priority 13 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via trusts and adjacents), proxy statements dominate (e.g., ADM, Newell, Philip Morris, Oshkosh) signaling peak governance season with May 2026 AGMs, board recommendations FOR comp plans/auditors amid neutral sentiment. Period-over-period trends show mixed revenue growth (e.g., Insight Molecular +116% YoY, Interlink +1.8% YoY, Worthington Steel +12% Q3 YoY) offset by widespread margin compression (Interlink gross -270bps YoY, Rockwell Q4 flat at 21% but FY sales -32% YoY) and cash deteriorations (Eltek ops cash -75% YoY to $1.1M, Rockwell ops cash used $659k vs provided $4.2M prior). Capital allocation leans shareholder-friendly in outliers (Oshkosh dividend +11.8% to $0.57, cash returned +73% YoY) but debt-heavy for M&A (Keurig €3B+$2.55B notes for JDE Peet’s). Forward-looking catalysts cluster in FDA reviews (Insight Q3 2026), acquisitions (Keurig by Feb 2027), and AGMs, with bullish alpha in diagnostics/health adjacents but bearish pressures from macro risks (Kornit inflation/overcapacity). Portfolio-level: 12/50 filings show revenue growth >10% YoY, but 8/20 with margin data average -150bps compression; staples-specific neutral on governance, mixed on financing.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like materials and construction amid sparse pure industrials), proxy season dominates with 15+ DEF/DEFA14A filings scheduling May 2026 annual meetings, signaling routine governance amid neutral-to-positive sentiment on board refreshes and comp approvals. FY2025 financials reveal mixed trends: revenue growth in select names like Paychex (+19.8% YoY Q3) and Iridex (+8% FY), but widespread loss widening in biotechs (e.g., Acumen +19%, Upstream +128%) and margin pressures (e.g., Evogene gross loss from inventory impairment); banks show NIM expansion (Farmers & Merchants +34 bps to 3.02%) offset by deposit declines (-5%). Capital returns shine with Newmont's $1.1B dividends/$3B buybacks and Banc of California's 8% share repurchase, while forward catalysts cluster in Q2 2026 (Rhythm EMA approval, multiple AGMs). Portfolio-level patterns include cost discipline (R&D/G&A cuts in 7/12 10-Ks averaging -25% YoY) amid cash burn, biotech regulatory tailwinds, and M&A like Corebridge-Equitable all-stock deal for $1.5T AUM scale. Implications: tactical buys in outperforming industrials like GE (passive Vanguard stake) and Newmont, caution on biotech cash drains; alpha from May proxy-driven volatility and Q2 catalysts.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 26, 2026

Across 12 SEC filings in the USA S&P 500 Energy intelligence stream (including midstream and LNG players like Targa Resources, Williams Companies, and Golar LNG), overarching themes include robust revenue growth in select reporters (e.g., Golar LNG +51% YoY, Galapagos NV +304% YoY) offset by rising costs, impairments, and margin pressures, with Williams Sonoma net earnings -3.3% YoY despite +1.2% revenue. Governance activity dominates with multiple proxy statements and board changes, notably Williams Companies reducing board size post-Alan Armstrong's resignation for U.S. Senate role, signaling leadership transitions in energy midstream. Capital allocation shows shareholder returns via buybacks ($862M at Williams Sonoma) and dividends ($327M), alongside capital raises like Peapack-Gladstone's $50M preferred stock. Forward-looking catalysts cluster around April-May 2026 AGMs and events like Enhanced Games launch, amid mixed sentiment (5/12 mixed or negative). Portfolio-level trends reveal 3/5 financial reporters with YoY revenue acceleration (avg +119%) but operating challenges (e.g., Golar expenses +31%, Galapagos R&D +37%), implying selective growth opportunities in energy services/LNG versus broader cost headwinds. Market implications favor monitoring midstream governance stability and LNG revenue momentum for near-term positioning.

10 high priority 2 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — March 26, 2026

Across 50 US SEC 8-K filings dated March 26, 2026, the dominant themes are pervasive executive turnover (20+ resignations/appointments across C-suite and boards), aggressive financing activity ($7M PIPE at Health In Tech, $475.9M at Wolfspeed, $250M credit at Stone Point), major M&A/divestitures (OLAPLEX buyout at 55% premium, Equitable-Corebridge $22B merger, SSR Mining $1.5B sale), and debt restructurings/extensions signaling liquidity strains in smaller caps. Limited period-over-period data shows Interlink Electronics with Q4 2025 revenue -4.5% YoY to $2.853M, gross margins -790 bps to 31.7%, but FY revenue +1.8% to $11.89M; no broad portfolio trends due to event-driven nature, but positive capital raises contrast one bankruptcy (Broad Street Realty). Critical developments include accretive mergers (Equitable-Corebridge >10% EPS accretion by 2028E), premium acquisitions, and experienced exec hires (Bloom Energy CFO, Vitesse CEO), implying sector transitions in energy/tech/finance; bearish signals from resignations and debt waivers highlight turnover risks. Market implications: Opportunities in M&A catalysts and post-financing pops, but watch liquidity/distress in microcaps amid high dilution risks.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 26, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily FY2025 10-Ks, 8-Ks, and proxy statements), overarching themes include a wave of proxy filings signaling May 2026 annual meetings for governance votes, mixed FY2025 financials with average revenue declines of ~12% YoY in 15/20 reporting companies (e.g., Shoe Carnival -5.6%, VirTra -15%, Identiv -19%) offset by cost cuts and margin improvements in 8/15 (e.g., CV Sciences gross margin +340 bps to 49%), and selective growth outliers like Galapagos NV +304% revenues to €1.11B. Capital allocation leans positive with dividend hikes (Shoe Carnival +11% to $0.60, Oshkosh +11.8% to $0.57) and buybacks (Banc of California 8% shares repurchased), but dilution risks from warrant exercises (Wheeler REIT 12% new shares) and shelf registrations (Kyverna $300M). Leadership transitions (Vitesse CEO change, CNH directors not re-electing) and biotech catalysts (Kyverna BLA 1H2026) provide upside, while retail/consumer and SPACs show weakness amid macro pressures. Portfolio-level, financials/banks exhibit NIM expansion (Hoyne +86 bps to 3.24%, Farmers & Merchants +34 bps to 3.02%), contrasting tech/manufacturing declines. Implications: Near-term proxy-driven volatility low materiality; focus on turnaround plays and dividend growers for defensive positioning.

27 high priority 23 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 26, 2026

Across 50 SEC filings for March 26, 2026, FY2025 results dominate with mixed outcomes: 14/22 10-Ks showed revenue growth averaging +15% YoY (e.g., Lumexa +7.8%, TXO +41.8%, Leef Brands +22.1%), but 10 reported widening net losses or impairments amid higher expenses/impairments (avg net loss expansion +12% YoY), signaling margin pressures in retail/REITs (Noodles -17.5% net loss YoY). SPAC/de-SPAC and M&A activity surges (12 filings, e.g., Suncrete non-redemptions +$105M PIPE, Xanadu $500M proceeds), indicating capital inflow for tech/quantum/industrials despite redemptions risks. Capital allocation leans shareholder-friendly (Williams Sonoma $862M buybacks + $327M dividends; News Corp $1B repurchase), but delistings (FiscalNote NYSE suspension) and delays (Genie Energy restatements, American Strategic earnings reschedule to Apr 14) flag governance risks. Healthcare outliers: Lumexa bullish (EBITDA +14.6% YoY, 2026 guidance $1.045-1.097B rev) vs Strata Skin rev -9% YoY. Energy mixed (TXO rev +42% but impairments; Canadian Nat reserves +4.5%). Portfolio implication: Favor growth diagnostics/energy over distressed retail/REITs; monitor SPAC closings for April catalysts.

35 high priority 15 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, gaming/entertainment proxies), overarching themes reveal mixed financial performance with revenue growth in 6/14 key operational reporters averaging +10% YoY (e.g., Ulta +9.7%, Laird +15%, SKYX +7%) offset by widespread margin compression averaging -120 bps (Laird -300 bps, Ulta -150 bps, Oxford ongoing pressures). Capital allocation leans shareholder-friendly with dividend hikes (Oxford to $0.70/share, First Bancorp declaration) and buybacks (Banc of California 8% shares repurchased), while M&A/integration (Laird/Navitas $38.5M) and debt optimization (Wolfspeed -43% notes redeemed, -13% debt) signal resilience. Proxies dominate (18/50 filings) clustering annual meetings in May 2026, highlighting governance catalysts amid neutral-to-positive sentiment. Portfolio-level trends show 4/10 consumer-facing firms guiding modest 2026 growth despite tariffs/commodity headwinds, with infra/funds (KKR +111% net ops) outperforming pure plays. Critical developments include Ulta's store expansion to 1,591 (+10%) and SKYX's gross margin to 30% (+100 bps), implying selective alpha in resilient retail/gaming vs. broader deterioration in legacy assets.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 26, 2026

Across 50 filings from the S&P 500 Healthcare stream and adjacent sectors, proxy statements dominate (e.g., Edwards Lifesciences, Centene, Alto Neuroscience) with neutral sentiment, setting up May 2026 annual meetings as key catalysts for director elections, auditor ratifications, and equity plan approvals. Financial results are mixed: small biotechs like Dare Bioscience (+10,429% YoY revenue from licenses) and STRATA Skin Sciences (-9% revenue but +49% operating loss improvement) show cost discipline narrowing losses despite revenue softness, while providers like Centene report challenging 2025 EPS ($2.08) but guide >$3.00 for 2026 (+40% YoY growth). Non-healthcare outliers like Corebridge Financial's $22B all-stock merger with Equitable (51/49 ownership split, $500M synergies by 2028, close YE2026) and Newmont's record 2025 FCF/$3B buybacks highlight capital returns, but healthcare trends emphasize R&D cuts (Dare -61% YoY) and positive pipeline catalysts (Artelo/Wave). Aggregate period trends: 7/12 reporting companies saw revenue declines averaging -10% YoY (e.g., CV Sciences -12%, STRATA -9%), but operating losses improved in 6/8 cases (avg +35% narrowing), signaling efficiency amid growth headwinds. Forward-looking optimism in biotech (e.g., Newsmax 13% rev growth FY26, though non-HC) contrasts with cash burn risks (Arcadia cash to $259K). Portfolio implication: Favor cost-cutters like Dare/CV Sciences for turnaround; monitor May proxies for governance shifts.

33 high priority 17 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 26, 2026

Across 50 DEF 14A proxy statements filed around March 26, 2026, a dominant theme is robust 2025 financial performance with 18/50 companies highlighting YoY revenue growth (avg +15% where quantified, e.g., Advanced Energy +21%, Liberty Media F1 +14%), record FCF in energy peers (CNX $646M, Peabody solid cash flow), and aggressive capital returns via buybacks ($3B Newmont, $528M CNX, 8% shares Banc CA) and dividend hikes (Oshkosh +11.8%, Hanover +5.6%). Exec comp is performance-aligned (79-95% at-risk/at equity in Tradeweb, Tractor Supply 89% variable), with high say-on-pay support (94.2% Eastern Bankshares, but KLX only 44.9%). Mixed signals in healthcare (Centene adj EPS $2.08 below outlook but 2026 >$3.00 +40% growth) and industrials (Oshkosh revenue -2.9% YoY). Governance strong: avg 85% board independence, diversity up (Tradeweb 55% indep, Invitation 40% diverse). No widespread insider selling noted; buybacks signal conviction. Portfolio trend: Bullish resource/energy (12/15 positive sentiment), neutral tech/healthcare; May 2026 meetings as catalysts for comp votes, declassifications.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 26, 2026

The IPO Pipeline stream shows heightened activity with two newly published SPAC-related filings (Maywood Acquisition Corp. 2 S-1 and Digital Asset Acquisition Corp. S-4) and one operating company IPO (CIMG Inc. S-1), all filed March 25-26, 2026, signaling a potential resurgence in SPAC and traditional IPO markets amid neutral sentiment across the board. Period-over-period data highlights SPAC IPO completions (e.g., Digital Asset's April 30, 2025 IPO) and CIMG's FY2025 financials with Q4 FY2025 trends, but lacks explicit YoY/QoQ growth numbers, focusing instead on structural setups like founder shares and concentrations. Key developments include Maywood's 10M unit IPO structure with 35% founder ownership post-offering, Digital Asset's de-SPAC with Old Glory (agreement Jan 13, 2026), and CIMG's acquisitions (e.g., Braincon Sep 23, 2025) amid customer/supplier concentrations. Portfolio-level patterns reveal standard SPAC dilution risks (founder shares at ~$0.01) and operating co risks from China/North America revenue splits, implying selective opportunities in monitoring IPO progressions. Market implications point to building catalyst calendars around S-1 effectiveness, business combinations, and warrant exercises, with high materiality (9-10/10) underscoring actionable intelligence for early positioning.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — March 26, 2026

Across 50 US SEC filings dated March 26, 2026, focused on global high-priority events, a mixed sentiment prevails with 18 mixed, 8 positive, 7 neutral, and 3 negative, highlighting financial distress (1 bankruptcy, multiple debt restructurings/amendments) juxtaposed against opportunistic financings and narrowing losses in biotechs/small caps. Period-over-period trends show revenue divergence: 12/25 quantifiable 10-K/10-Qs reported YoY declines averaging -7.5% (e.g., Lands' End -2%, NORTECH -7.6%, VirTra -15%), while 13 showed growth averaging +72% (e.g., AmpliTech +165%, Nyxoah +122%, Spero +39%), with margins expanding in 8/15 cases (avg +210 bps, e.g., Lands' End +80 bps, NORTECH +210 bps). Biotech/pharma cluster (10 filings) averaged net loss narrowing 25% YoY amid R&D cuts, but cash burns persisted; retail/apparel saw uniform sales drops (-2% to -5.6%). Capital allocation leans defensive (dividend hikes in Shoe Carnival +11%, Lands' End implied stability; Newmont $3B buybacks), with forward catalysts clustering in May 2026 proxy votes (15+ meetings) and debt/acquisition milestones (Keurig JDE Peet's by Feb 2027). Critical implications: imminent liquidation risks (Broad Street Realty), dilution threats (Sadbhav MRA equity conversions, Wytec warrants), but alpha in turnaround plays (Spero swung to profit) and growth outliers (Paychex +19.8% revenue). Portfolio pattern: monitor small-cap distress vs. large-cap stability for relative outperformance.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 26, 2026

Two US-listed companies, FiscalNote Holdings (NOTE) and Cambium Networks (CMBM), faced delisting notices on March 25, 2026, triggering immediate or imminent trading suspensions due to failure to meet exchange listing rules—low average share price for NOTE (below $1.00 over 30 trading days) and non-compliance with prior Nasdaq decision for CMBM. Trading for NOTE (common and warrants NOTE.WS) suspended immediately on NYSE, shifting to OTC Markets on March 26, 2026; CMBM suspension effective March 27 open on Nasdaq, moving to OTCID. No enriched period-over-period financial trends, insider activity, capital allocation, or forward-looking guidance provided in filings, limiting quantitative comparisons, but both exhibit negative sentiment (10/10 materiality) with potential material adverse effects on share price and liquidity. Overarching theme: heightened regulatory pressure on low-priced small-cap stocks, signaling portfolio-level risks in compliance-challenged names. Investors face immediate liquidity and valuation risks, with appeals possible but uncertain outcomes; no impact on operations or SEC reporting noted.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 26, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity management through debt amendments/extensions (e.g., WYTEC, Profusa, Diameter Credit), equity raises (Health In Tech $7M PIPE, SmartKem $2.6M), and new credit facilities (Stone Point $250M revolver, Masco $1B), signaling ongoing distress but proactive refinancing amid high interest rates. Outright distress peaks with Broad Street Realty's Chapter 7 bankruptcy liquidation and delistings for FiscalNote (NYSE to OTC) and Cambium Networks (Nasdaq suspension March 27, 2026), while reverse splits (Advantage Solutions 1:25) highlight share price pressures. Period-over-period trends show mixed resilience: Synchrony Card portfolio payment rates up to 24.29% monthly avg in 2026 vs 23.47% in 2025 with 95.1% current accounts; MeiraGTx service revenue -81% YoY but net loss improved 23% to $114.2M. Positive M&A catalysts like OLAPLEX $1.4B sale (55% premium), SSR Mining $1.5B asset sale (Q3 2026 close), and Equitable-Corebridge $22B merger (10% EPS accretion by 2028) offer deleveraging paths. Capital allocation leans toward debt reduction/repayment (Wolfspeed $475.9M refinancing saves $62M annual interest), with no major dividend cuts but dilution risks from warrants/equity. Overall, 7/31 filings indicate severe distress (bankruptcy/delistings), but 15+ show financing successes, implying selective opportunities in refinancings vs high bankruptcy risk in microcaps.

31 high priority 31 total filings
· daily

US Executive Officer Management Changes SEC — March 26, 2026

Across 43 filings on USA executive and director changes from March 26, 2026, the dominant theme is leadership transitions with 22 appointments (experienced hires in energy, tech, banking) versus 18 resignations/departures, mostly neutral sentiment but positive on strategic hires like Vitesse Energy's new CEO and Bloom Energy's CFO. Period-over-period data limited but notable: Interlink Electronics Q4 2025 revenue -4.5% YoY to $2.853M, gross margin -790 bps to 31.7%, though FY revenue +1.8% to $11.89M with net loss improved -19% to -$1.615M. No widespread insider trading or capital allocation shifts, but compensation enhancements (e.g., Meritage Homes CEO target $4M cash +$6M equity, Alight TVR awards up to 8.25M shares) signal retention focus. Positive hires boost conviction in growth sectors like AI/energy (Bloom, 3D Systems), while sudden CFO exits (RetinalGenix, MetroCity) flag risks. Portfolio implication: Monitor energy/utilities (6 filings) for stability, tech/biotech (12 filings) for innovation acceleration; overall neutral-to-positive for long-term value via succession planning.

43 high priority 43 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 26, 2026

Broad Street Realty, Inc., the sole filing in this USA Bankruptcy & Insolvency stream, voluntarily petitioned for Chapter 7 bankruptcy on March 20, 2026, in the U.S. Bankruptcy Court for the District of Delaware (Case No. 26-10398-KBO), signaling total liquidation and cessation as a going concern. George L. Miller was appointed Chapter 7 Trustee to oversee asset liquidation and creditor payments, immediately stripping the Board of Directors and executives of all authority. CFO Alexander Topchy resigned effective the same date, underscoring acute management distress amid the collapse. No period-over-period financial trends or forward-looking guidance are viable post-filing, as operations end; sentiment is uniformly negative with 10/10 materiality. This development implies imminent equity wipeout, with portfolio implications for real estate exposure: delisting likely, zero recovery for shareholders. Overarching theme: isolated but extreme insolvency event highlights vulnerability in commercial realty amid presumed prior deteriorating metrics like rising debt or occupancy declines.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 26, 2026

Across 43 filings on USA Board Room Changes from March 26, 2026, the dominant theme is elevated C-suite and board turnover, with 18 CFO/CAO/Principal Accounting Officer changes (e.g., retirements, resignations, appointments), 12 CEO/President shifts, and 15+ board director additions/resignations/not standing for re-election, signaling proactive refreshes amid strategic pivots. Positive sentiment prevails in 12 cases (e.g., experienced hires in energy/tech like Vitesse CEO Jamie Benard, Bloom CFO Simon Edwards), neutral in 26, negative/mixed in 5, with materiality averaging 6/10 and peaking at 9/10 for Vitesse, Apimeds dispute, Skywater transaction. Sparse period-over-period data shows Interlink Electronics Q4 2025 revenue -4.5% YoY ($2.853M vs $2.986M), FY +1.8% ($11.89M), gross margins -780bps Q4/-260bps FY, highlighting product mix pressures; no broad deteriorating trends but isolated losses improving FY net loss -18.6% YoY. Forward-looking catalysts cluster around May 2026 AGMs (Macy's May 15, Auburn May 12) and Q2 transitions (Vitesse May 1 CEO). Portfolio implications: Bullish for leadership upgrades in growth sectors (energy, tech), bearish execution risks in finance CFO churn; monitor for insider conviction via post-change trading.

43 high priority 43 total filings
· daily

US Merger & Acquisition SEC Filings — March 26, 2026

The 8 filings highlight intense SPAC maneuvering amid M&A completions in niche sectors like crypto blockchain and industrial/pharma mergers, with 5/8 filings from blank-check companies (Soulpower, Launch One, Haymaker, IB, Metal Sky) showing extension efforts, financings, and governance changes versus 3 actual deal closures (Atlantic, Crypto Co, Enzon). Key trends include heavy SPAC redemptions (e.g., IB's $7.9M outflow leaving $8.2M trust) and sponsor support via notes/preferred stock, signaling prolonged hunts for targets; no broad YoY/QoQ financial trends reported but capital raises average ~$1.25M principal across notes/preferred for working capital/BC. Positive catalysts emerge from Crypto Co's milestone-based IP acquisition with 2026 blockchain launch and Enzon's all-stock merger (45/55 ownership split), boosting interoperability and operational scale. Mixed sentiment prevails (3 neutral, 2 positive, 1 mixed) with materiality skewed high (5/8 at 7-9/10) on deal-related filings, implying near-term volatility in SPACs but alpha in completed M&A. Portfolio-level pattern: SPACs face redemption pressures (1/5 with quantified $7.9M drain) versus accretive deals with no upfront dilution.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 26, 2026

Across 50 overnight SEC filings for March 25-26, 2026, FY2025 results dominate with mixed outcomes: 12/20 major 10-Ks showed revenue growth averaging +12% YoY (e.g., Lumexa +7.8%, Leef Brands +22.1%, TXO Partners +41.8%), but net losses widened in 8/20 cases amid impairments, higher expenses, and debt costs; REITs and BDCs exhibited portfolio stress with yields declining (BlackRock Multifamily 4.5%, AB Private Credit 9.58% vs 10.51%). SPAC/de-SPAC momentum is strong with 8 filings advancing mergers (Suncrete non-redemptions, Enhanced Games IPO path, Xanadu $500M proceeds), signaling M&A alpha in tech/AI/quantum. Capital allocation leans defensive: buybacks (Williams Sonoma $862M, News Corp $1B program), dividends stable, but leverage rose in energy (TXO +85%). Healthcare/imaging outperforms (Lumexa advanced procedures +14.2% Q4 YoY, leverage down to 3.5x), while banks face NIM expansion offset by provisions (United Security ROA - to 1.01%). Delistings (FiscalNote) and restatements (Genie Energy) flag risks; forward catalysts cluster in Q2 (proxies, earnings April-May). Overall, selective bullishness in growth niches amid broad profitability pressure, favoring de-SPACs and reiterated guidance plays pre-open.

35 high priority 15 medium 50 total filings